by Micah Harman | Jan 17, 2025 | News & Media, Interviews/Speaking/Events
Executives attending J.P. Morgan conference don’t expect to find easy money in 2025 By Rowan Walrath C&EN Cartography Biosciences CEO Kevin Parker doesn’t see 2025 being much better than 2024 when it comes to financing opportunities for biotechnology companies... by Micah Harman | Jan 8, 2025 | Press Releases, Interviews/Speaking/Events, News & Media
LEHI, Utah, Jan. 8, 2025 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today that its leadership team will attend and participate in a panel... by Micah Harman | Dec 18, 2024 | News & Media, Interviews/Speaking/Events
Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves hematologic response in lower-risk MDS. Jordyn Sava December 17, 2024 The second stage of a phase 2 trial exploring the first-in-class allosteric... by Micah Harman | Nov 13, 2024 | Interviews/Speaking/Events, News & Media
David Wild interviews David Bearss, CEO of Halia Therapeutics Read the article here by Micah Harman | Oct 31, 2024 | Press Releases, Interviews/Speaking/Events
HT-6184 Shows Enhanced and Sustained Weight Loss with GLP-1 Agonist Combination for Obesity LEHI, Utah, October 31, 2024 /PRNewswire/—Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments for chronic... by Micah Harman | Oct 16, 2024 | Interviews/Speaking/Events, News & Media
BIO News BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? BIF 2024: What’s happening with neurodegenerative disease targets and pipelines? Clary Estes October 15, 2024 There is a great degree of renewed optimism for drug... by Micah Harman | Oct 14, 2024 | Press Releases, Interviews/Speaking/Events
Dr. David J. Bearss, CEO, will partake in a panel focused on Neurodegenerative Disease Targets and Pipelines on Tuesday, October 15 at 11:00-11:50 am PT LEHI, Utah, Oct. 14, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage... by Halia Therapeutics | Oct 4, 2024 | News & Media, Interviews/Speaking/Events
Listen to Dr David Bearss discuss Halia’s work on Alzheimer’s and other inflammation-related diseases https://podcasts.apple.com/us/podcast/dr-dave-bearss-co-founder-ceo-of-halia-on-pioneering/id1482108463?i=1000671780322 Explore the forefront of biotech... by Halia Therapeutics | Sep 3, 2024 | News & Media, Interviews/Speaking/Events
For decades drugmakers have taken a more-is-more model when dosing cancer drugs in clinical trials. U.S. regulators want them to reconsider that approach. Companies with cancer drugs in clinical trials must strike a balance between doses high enough to thwart...